Printer Friendly

EPITOPE RESPONDS TO UNUSUAL STOCK ACTIVITY

EPITOPE RESPONDS TO UNUSUAL STOCK ACTIVITY
 BEAVERTON, Ore., June 15 /PRNewswire/ -- Epitope, Inc. (AMEX: EPT), today issued a response to questions and rumors which circulated last week concerning the company's Premarket Approval Application (PMA) filed with the Food and Drug Administration (FDA) to allow sales of Epitope's OraSure(R) oral specimen collection device. Epitope's common stock closed at 16-1/8 on Friday, down 2-1/2 in heavy trading.
 "On April 30, 1992, the FDA issued a document to the company containing observations previously communicated to Epitope by FDA staff as a result of visits in November and December 1991. The visits and the document are part of procedures followed by the agency as part of the PMA review process. These issues had already been addressed with FDA staff and/or in a PMA amendment submitted to the FDA by Epitope in mid- April," said Adolph J. Ferro, president and chief executive officer.
 Epitope, Inc., is an Oregon corporation using biotechnology to develop diagnostic tests for AIDS and other indications, therapeutic antiprotozoal drugs and, through its agricultural unit, Agritope, Inc., superior new plant varieties.
 -0- 06/15/92
 CONTACT: Mary Hagen, 503-641-6115, or Shari Annes, 415-726-5400, both for Epitope
 (EPT) CO: EPITOPE, INC. IN: MTC ST: OR -- NY022 -- X436 06/15/92
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 15, 1992
Words:211
Previous Article:1992 BEST'S RATINGS ASSIGNED TO 304 COMPANIES INCLUDING 11 LARGE INSURERS
Next Article:U.S. SURGICAL BELIEVES NEW YORK TIMES ARTICLE ON LAPAROSCOPIC SURGERY MISLEADING
Topics:


Related Articles
EPITOPE REPORTS FIRST-QUARTER RESULTS
EPITOPE ANNOUNCES GLOBAL MARKETING/MANUFACTURING PACTS AT SHAREHOLDERS' MEETING
EXERCISE PRICE SET FOR EPITOPE WARRANTS TO BE ISSUED FOR CLASS ACTION SETTLEMENT
EPITOPE AND KIPKE SETTLE LAWSUIT
EPITOPE SEEKS COURT APPROVAL TO EXTEND DEADLINE FOR EXERCISE OF WARRANTS BY 60 DAYS
EPITOPE NAMES SCOTT RAIRIGH AS MEDICAL PRODUCTS SALES MANAGER
Epitope Announces First Quarter Operating Results
Epitope Announces Second Quarter Operating Results
/C O R R E C T I O N -- Epitope, Inc./ (Credit Ratings)
Record Date Set For Agritope Spin-Off

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters